RESUMEN
We report a lateral rectus muscle paralysis occurring 2 weeks after initiation of an interferon-α and ribavirin treatment in a patient with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) virus co-infection. This patient presented with horizontal diplopia that appeared rapidly and without any other neurological symptoms. Symptoms fully resolved with treatment interruption without any ophthalmological sequelae. This side effect is rare and has never been reported in a HIV-HCV co-infected patient.
Asunto(s)
Enfermedades del Nervio Abducens/inducido químicamente , Antivirales/efectos adversos , Infecciones por VIH/tratamiento farmacológico , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/efectos adversos , Polietilenglicoles/efectos adversos , Ribavirina/efectos adversos , Enfermedades del Nervio Abducens/diagnóstico , Adulto , Antivirales/uso terapéutico , Ojo/efectos de los fármacos , Ojo/fisiopatología , Infecciones por VIH/virología , Hepatitis C Crónica/virología , Humanos , Interferón-alfa/uso terapéutico , Masculino , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/fisiopatología , Polietilenglicoles/uso terapéutico , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/uso terapéutico , Ribavirina/uso terapéuticoRESUMEN
The efficacy and tolerance of telaprevir (TVR) was examined in 20 mostly cirrhotic HIV-hepatitis C genotype 1 (HCV-G1)-infected patients failing previous treatment with pegylated-interferon and ribavirin (PR). HCV-RNA less than 12âIU/ml was observed in 35.3% of patients at W2, 55.0% at W4, 65.0% at W12 and 55.0% at W24. All patients with virological failure (nâ=â9) exhibited V36M/R155K mutations. Early virological response was a determinant of HCV-RNA less than 12âIU/ml at W24 (Pâ<â0.001). No grade 3-4 dermatological side-effects were reported. TVR-PR tritherapy appeared to be rather effective and well tolerated among difficult-to-treat HIV-HCV-G1 patients.